Presented by Dr Masafumi Ikeda (National Cancer Center Hospital East, Kashiwa, Japan)
The GEMINI-Hepatobiliary phase 2 study evaluated the efficacy of the anti-PD-1/TIGIT bispecific antibody, rilvegostomig (rilve), combined with chemotherapy (gemcitabine and cisplatin) in patients with advanced biliary tract cancer (BTC). In Cohort A, rilve plus chemotherapy showed a promising 6-month PFS e plus chemotherapy showed a promising 6-month PFS rate of 73.0%, with a median PFS of 8.3 months. Patients with PD-L1 tumor area positivity ≥1% had a numerically longer PFS. The safety profile was manageable, and rilve achieved >90% receptor occupancy on peripheral T cells, inducing T cell proliferation. Further follow-up is needed to mature the data.
References:
Ikeda M. et al, ASCO 2025, abstract # 4080
Donderdag 12 november 2026
Kontich
Gent
Linter
Onthaal vanaf 18 uur
Programma van 19 tot 22 uur
Kies jouw locatie en schrijf je in
Donderdag 12 november 2026
Kontich
Gent
Linter
Onthaal vanaf 18 uur
Programma van 19 tot 22 uur
Kies jouw locatie en schrijf je in